4,900 Shares in AstraZeneca PLC (NASDAQ:AZN) Purchased by Barometer Capital Management Inc.

Barometer Capital Management Inc. bought a new position in AstraZeneca PLC (NASDAQ:AZNFree Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 4,900 shares of the company’s stock, valued at approximately $332,000.

A number of other institutional investors have also recently made changes to their positions in the business. LPL Financial LLC increased its holdings in AstraZeneca by 24.9% in the 2nd quarter. LPL Financial LLC now owns 320,876 shares of the company’s stock worth $22,965,000 after buying an additional 63,872 shares during the period. Truist Financial Corp boosted its stake in shares of AstraZeneca by 2.8% in the second quarter. Truist Financial Corp now owns 247,269 shares of the company’s stock worth $17,697,000 after buying an additional 6,741 shares during the last quarter. Barclays PLC lifted its holdings in AstraZeneca by 317.4% in the third quarter. Barclays PLC now owns 1,242,431 shares of the company’s stock valued at $84,136,000 after acquiring an additional 944,765 shares during the period. 1832 Asset Management L.P. boosted its position in AstraZeneca by 18.9% in the 2nd quarter. 1832 Asset Management L.P. now owns 2,134,805 shares of the company’s stock worth $152,788,000 after purchasing an additional 338,896 shares in the last quarter. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of AstraZeneca during the 3rd quarter worth approximately $2,241,000. Institutional investors and hedge funds own 15.68% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on AZN shares. Jefferies Financial Group lowered shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. HSBC initiated coverage on AstraZeneca in a report on Monday, December 18th. They issued a “buy” rating for the company. Finally, Morgan Stanley initiated coverage on AstraZeneca in a research report on Tuesday, January 23rd. They issued an “overweight” rating for the company. Three equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $80.00.

Read Our Latest Research Report on AZN

AstraZeneca Trading Down 0.5 %

Shares of AZN traded down $0.33 during midday trading on Monday, reaching $65.31. The company had a trading volume of 1,289,717 shares, compared to its average volume of 5,471,551. The company has a quick ratio of 0.60, a current ratio of 0.79 and a debt-to-equity ratio of 0.60. AstraZeneca PLC has a 1-year low of $61.73 and a 1-year high of $76.56. The firm has a 50 day simple moving average of $66.42 and a 200-day simple moving average of $66.84. The stock has a market cap of $202.48 billion, a PE ratio of 34.55, a price-to-earnings-growth ratio of 1.17 and a beta of 0.52.

AstraZeneca (NASDAQ:AZNGet Free Report) last posted its earnings results on Wednesday, November 8th. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.03. AstraZeneca had a net margin of 13.10% and a return on equity of 30.30%. The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $11.55 billion. During the same period in the previous year, the business posted $0.84 EPS. AstraZeneca’s revenue was up 4.6% on a year-over-year basis. Research analysts forecast that AstraZeneca PLC will post 3.66 EPS for the current fiscal year.

AstraZeneca Company Profile

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Further Reading

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZNFree Report).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.